ArticleFrontiers in molecular biosciences2025
Integrating multi-dimensional data to reveal the mechanisms and molecular targets of baikening granules for treatment of pediatric influenza.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Children are the main group affected by the influenza virus, posing challenges to their health. The high risk of viral variability, drug resistance, and drug development leads to a scarcity of therapeutic drugs. Baikening (BKN) granules are a marketed traditional Chinese medicine used to treat children's lung heat, asthma, whooping cough, etc. Therefore, exploring the potential mechanisms of BKN in treating pediatric influenza is of great significance for discovering new drugs. Methods: Through the database, we obtained differentially expressed genes (DEGs) between pediatric influenza and healthy samples, identified the components of BKN, and collected the targets. Target networks were built with the purpose of screening both targets and key components. Pathway and function enrichment were conducted on the relevant targets of BKN for treating pediatric influenza. BKN-related hub genes for influenza were discovered through DEGs, weighted gene co-expression network analysis (WGCNA), BKN-cluster WGCNA, and machine learning model. The accuracy of prediction efficiency and the value of BKN-related hub gene were validated through analysis of external datasets and receiver operating characteristics. Ultimately, simulations using molecular docking and molecular dynamics were used to forecast how active components will bind to hub genes. Result: A total of 20 candidate active compounds, 58 potential targets, and 3,819 DEGs were identified. The target network screened the top 10 key components and 6 core targets (PPARG, MMP2, GSK3B, PARP1, CCNA2, and IGF1). Potential target enrichment analysis indicated that BKN may be involved in AMPK signaling pathway, PI3K Akt signaling pathway, etc., to combat pediatric influenza. Subsequently, two hub genes (OTOF, IFI27) were obtained through WGCNA, BKN-cluster WGCNA, and machine learning models as potential biomarkers for BKN-related pediatric influenza. Two hub genes were found to have primary diagnostic value based on ROC curve analysis. Molecular docking confirmed the binding between BKN and hub gene. Molecular dynamics further revealed the stable binding between Peimisine and hub genes. Conclusion: BKN may alleviate pediatric influenza via key components targeting core targets (PPARG, MMP2, GSK3B, PARP1, CCNA2, and IGF1) and hub genes (OTOF, IFI27), with the involvement of feature genes-related pathways. These results have potential consequences for future research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.